Is OMER a Buy or a Sell? The Bull and Bear Case (2026)
Last updated July 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Omeros (OMER) rests on The YARTEMLEA launch curve: TA-TMA has no approved competitor, which is unusual and is the whole reason the launch has moved this fast: gross sales went from about $11.1 million in the first quarter of 2026 to about $32.2 million in the second, with gross-to-net deductions running near 11.5 percent. The bear case rests on concentration is the first-order risk: one drug, one indication, one country generating essentially all product revenue, with a patient population measured in the low thousands per year. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Omeros Corporation develops drugs that target the complement system, the part of innate immunity that turns destructive in certain rare diseases. Its lead product, YARTEMLEA (narsoplimab-wuug), is a MASP-2 antibody approved by the FDA in December 2025 for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adults and children two and older, a condition with high mortality and, until that approval, no approved treatment. Omeros also earns a royalty tail on OMIDRIA, the ophthalmic surgical drug it sold to Rayner in 2021, and in December 2025 it closed a deal handing global rights to its MASP-3 inhibitor zaltenibart (OMS906) to Novo Nordisk for $240 million in cash up front and up to $2.1 billion in total potential payments plus royalties. What remains in house is earlier stage: OMS1029, a long-acting MASP-2 antibody designed for quarterly dosing, and OMS527, a PDE7 inhibitor funded by NIDA for cocaine use disorder. The investment picture changed twice in eight months. The Novo Nordisk transaction converted a clinical asset into cash, which Omeros has been spending on retiring its 2029 convertible notes rather than on new trials, and the YARTEMLEA launch turned a company with no product revenue into one reporting about $28.5 million of net product sales in the second quarter of 2026, up from roughly $9.9 million in the first. Second-quarter net income was about $13.2 million and operating cash flow was positive. Trailing-twelve-month revenue therefore looks tiny relative to the roughly $1.0 billion market value, but that is an artifact of a product that only started selling in January 2026; the second-quarter run rate is a far more useful denominator. The offsetting facts are that essentially all commercial revenue comes from one drug in one indication, that Europe's CHMP adopted a negative opinion on narsoplimab in June 2026 and sent the stock down about 19 percent in a day, and that several plaintiffs' firms opened investigations after that drop.
The bull case for OMER
1. The YARTEMLEA launch curve
TA-TMA has no approved competitor, which is unusual and is the whole reason the launch has moved this fast: gross sales went from about $11.1 million in the first quarter of 2026 to about $32.2 million in the second, with gross-to-net deductions running near 11.5 percent. The relevant question for the next few quarters is whether that reflects durable adoption at transplant centers or an initial wave of prevalent patients being treated at once. Reorder rates and the number of accounts actually dosing, rather than headline growth, are what separate the two.
2. A repaired balance sheet, not a raised one
The $240 million Novo Nordisk upfront arrived without issuing shares, and management has used the proceeds to buy back convertible debt: the 2029 notes were cut to roughly $55 million of principal by June 30, 2026, with more retired after the quarter, and a modest amount of stock was repurchased alongside. That removes future interest cost and potential dilution from a company that historically funded itself by selling equity and royalties. Cash and short-term investments stood near $132 million at the end of the quarter.
3. The OMIDRIA royalty tail and the Novo milestones
OMIDRIA still generates royalties on Rayner's US net sales through 2031, reported inside discontinued operations, and contributed about $6.6 million of net income in the second quarter. Part of that stream was previously monetized to DRI Healthcare, so the economics reaching Omeros are smaller than headline OMIDRIA sales suggest. Separately, zaltenibart milestones from Novo Nordisk are development and sales driven, which makes them real but unscheduled: they are optionality on someone else's trial timelines, not something to model as recurring.
4. Europe, label expansion and the rest of the pipeline
The CHMP negative opinion in June 2026 removed the near-term European contribution and Omeros has requested a re-examination with external expert review, an outcome that will be known later in the year. Beyond that, the in-house pipeline is thin by design after the zaltenibart sale: OMS1029 has completed Phase 1 work supporting quarterly dosing, and OMS527 is expected to begin clinical enrollment for cocaine use disorder around the end of 2026. Neither is close to contributing revenue, so pipeline value here is a call option rather than a second engine.
The bear case for OMER
Concentration is the first-order risk: one drug, one indication, one country generating essentially all product revenue, with a patient population measured in the low thousands per year. A launch that looks steep for two quarters can flatten quickly once prevalent patients are treated, and rare-disease reimbursement can widen gross-to-net deductions over time. The June 2026 CHMP negative opinion is a live setback, and re-examinations more often confirm than reverse an opinion, so European revenue should not be assumed. Several plaintiffs' firms announced investigations after the resulting share-price drop, and while no filed class action complaint was found, an investigation can turn into one. The company also still carries convertible notes and a shareholders' deficit, so a stumble in the launch would put financing back on the table for a business that has raised money on unfavorable terms before.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding OMER already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on OMER
Too few analysts publish on OMER for a consensus target to mean anything, so there is no professional average to weigh against your own view. That cuts both ways: less informed opinion to lean on, and less of it already priced in. The OMER forecast page covers what coverage does exist.
How is OMER valued? (as of August 2026)
Snapshot for OMER as of August 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Net product revenue (Q2 2026): ~$28.5M (~$32.2M gross)
- Net product revenue (H1 2026): ~$38.4M, versus $0 a year earlier
- Net income (Q2 2026): ~$13.2M, or ~$0.18 per share
- Cash and short-term investments: ~$132M as of June 30, 2026
- 2029 convertible notes: ~$55M principal at June 30, reduced further after quarter end
- Market cap: ~$1.0B on ~72M shares outstanding
Screens that show Omeros at roughly 100 times sales are reading a trailing window that mostly predates the product: YARTEMLEA only began selling in January 2026. Against the second-quarter net revenue run rate of about $114 million annualized, the same market value is closer to nine times sales, which is an ordinary multiple for a rare-disease launch and a demanding one if the ramp stalls. Reported profitability is also flattered by one-time items, since first-half net income of about $69.3 million includes the Novo Nordisk transaction rather than recurring operations.
How do you decide if OMER is a buy?
Rather than asking whether OMER is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold OMER indirectly through an index or sector ETF before adding more.
What would change your mind on OMER
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: The YARTEMLEA launch curve stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: concentration is the first-order risk: one drug, one indication, one country generating essentially all product revenue, with a patient population measured in the low thousands per year fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the OMER stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about OMER against your real portfolio and see your actual exposure before deciding.
Investing in Omeros with AI
Connect the broker you already use and ask Walnut's AI how OMER fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is OMER a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on The YARTEMLEA launch curve, with net product revenue (q2 2026) at ~$28.5M (~$32.2M gross). The bear case rests on concentration is the first-order risk: one drug, one indication, one country generating essentially all product revenue, with a patient population measured in the low thousands per year. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell OMER?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Concentration is the first-order risk: one drug, one indication, one country generating essentially all product revenue, with a patient population measured in the low thousands per year. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. Walnut is not an investment adviser.
What is the bull case for OMER?
+
The YARTEMLEA launch curve. TA-TMA has no approved competitor, which is unusual and is the whole reason the launch has moved this fast: gross sales went from about $11.1 million in the first quarter of 2026 to about $32.2 million in the second, with gross-to-net deductions running near 11.5 percent.
What is the bear case for OMER?
+
Concentration is the first-order risk: one drug, one indication, one country generating essentially all product revenue, with a patient population measured in the low thousands per year. A launch that looks steep for two quarters can flatten quickly once prevalent patients are treated, and rare-disease reimbursement can widen gross-to-net deductions over time. The June 2026 CHMP negative opinion is a live setback, and re-examinations more often confirm than reverse an opinion, so European revenue should not be assumed. Several plaintiffs' firms announced investigations after the resulting share-price drop, and while no filed class action complaint was found, an investigation can turn into one. The company also still carries convertible notes and a shareholders' deficit, so a stumble in the launch would put financing back on the table for a business that has raised money on unfavorable terms before.
What does Omeros do?
+
Complement-system drug developer whose first approved product treats transplant-associated thrombotic microangiopathy, launched in the United States in early 2026.
What would have to change for OMER to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (The YARTEMLEA launch curve) stalling in the reported numbers rather than in the narrative, the risk above (concentration is the first-order risk: one drug, one indication, one country generating essentially all product revenue, with a patient population measured in the low thousands per year) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Omeros actually sell today?
+
One approved product. YARTEMLEA (narsoplimab-wuug) was approved by the FDA on December 23, 2025 for hematopoietic stem cell transplant-associated thrombotic microangiopathy in patients two and older, and it is the first lectin-pathway inhibitor to reach the market. Omeros also collects royalties on OMIDRIA, the eye-surgery drug it sold to Rayner in 2021, which are reported inside discontinued operations rather than as product revenue.
Is Omeros still a clinical-stage biotech?
+
No, not since the end of 2025. It reported about $28.5 million of net product revenue in the second quarter of 2026 and about $13.2 million of net income, with positive operating cash flow. What remains in house is early: OMS1029, a long-acting MASP-2 antibody that has finished Phase 1, and OMS527 for cocaine use disorder. So it is a commercial company with a thin pipeline rather than a pre-revenue one.
Why does OMER look like it trades at 100 times sales?
+
Because the trailing-twelve-month figure on most screeners still covers quarters when the company had no product to sell. YARTEMLEA launched in January 2026, so the trailing number captures roughly two quarters of sales at most. Measured against the second-quarter run rate of about $114 million annualized, the roughly $1.0 billion market value works out closer to nine times sales. Whether that is cheap depends entirely on the launch continuing.
Walnut is informational, not investment advice, and gives no verdict on OMER. Analyst targets referenced here come from a August 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.